CeriBell, Inc. — Cyborg Score 4/10

Mixed
Medical Devices & Technology - Neurological Diagnostics / Point-of-Care EEG

Strategic Profile

CeriBell is a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions through the Ceribell System, a novel, point-of-care electroencephalography (EEG) platform. The system combines proprietary, highly portable, and rapidly deployable hardware with sophisticated artificial intelligence-powered algorithms. The company received FDA 510(k) clearance for its Clarity algorithm, becoming the first and only AI-powered point-of-care EEG system cleared to detect electrographic seizures, supported by data from over 1,700 patients.

Cyborg Score Rationale

CeriBell had a negative return on equity of 31.77% and a negative net margin of 59.97% in Q4 2025. The company has a market cap of $680.62 million, a PE ratio of -12.38. Despite unprofitability, analysts have given a consensus recommendation of "Moderate Buy", with five buy ratings and one strong buy rating. The company shows strong revenue growth momentum offset by near-term profitability challenges.

Top Insights

  • Q4 2025 performance driven by product revenue of $15.9 million (up 38%) and subscription revenue of $5.3 million (up 41%).
  • The company maintains a strong financial position with $177.4 million in cash and equivalents.
  • CeriBell is the only medical device company with FedRAMP High Authorization and is already deployed in VA hospitals, enabling expansion into federal healthcare.
  • The company generates revenue from disposable headband sales and monthly subscription fees charged to hospital customers for Clarity, recorders, and portal access.

Named Competitors

  • Traditional EEG Monitoring Systems — Bedside EEG systems without portable, point-of-care capability
  • Cloud-based EEG Management Platforms — Remote EEG review and interpretation software (non-portable hardware)
  • Hearing Screening Devices (legacy business) — Automated newborn hearing screening solutions

Recent Developments

  • (February 2026) Q4 2025 earnings beat: reported ($0.36) EPS vs. ($0.43) estimate; revenue $24.78M beat expectations
  • (August 2025) CEO Jane Chao presented at Canaccord Genuity 45th Annual Growth Conference
  • (2025) Received FedRAMP High Authorization for secure cloud-based solution, enabling expansion across federal healthcare facilities including VA hospitals

Open the full interactive CeriBell, Inc. report

Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.

Open report →